Protéus and ARD announced a natural collaboration for Green Chemistry
Protéus announces collaboration with Syngenta in Biofuels
The companies will develop new enzymes for the creation of next generation biofuels
Nîmes, France, January 15, 2009 - Proteus announced today that it has entered into a collaboration agreement with agribusiness leader, Syngenta. The two companies will work together on the development of novel high performing enzymes for next generation biofuel production. Both diversity screening and directed evolution methods will be used for the discovery and the optimization of such targeted enzymes for the conversion of biomass into biofuels.
“We believe that our strategy based on optimized enzymes holds tremendous potential for the creation of next generation biofuels,” remarked Dr. Ian Jepson, Head of Enzymes R&D at Syngenta. “The collaboration with Proteus helps us to accelerate development by offering technology that complements our core skills in plant expression.”
“Through the confidence of an industrial company leader in its domain, the expertise and technologies of Protéus are once again recognized. I am very pleased that we are working with Syngenta to develop new biotechnology processes that will bring benefits for future generations” said Dr Gilles Ravot,
CEO of Protéus.
Further details of the agreement were not disclosed.
Protéus is a worldwide recognized biotechnology company which focuses on the discovery, engineering and manufacturing of proteins of industrial interest, and on the development of innovative protein-based bioprocesses. The efficiency of Proteus' technology platform has been demonstrated by the successful track record of the company in the life sciences industry, including healthcare, chemistry (fine or specialty chemicals), environment and bioenergy.
Protéus reinforces the competitive edge of its clients by providing them new industrial solutions and new industrial property rights. The comprehensive offering of Protéus includes industrial manufacturing capabilities to accelerate the development, the industrialization and the time-to-market of its clients' new products.
In order to fulfill this mission, Protéus possesses unique proprietary technologies including an exclusive biodiversity (source of new genes), protein engineering tools (for the delivery of bespoke enzymes for industrial application) and a protein manufacturing platform, allowing use of proteins as new industrial
For more information : www.proteus.fr
For more information, please contact :
Andrew Lloyd & Associates
Neil Hunter / Andrew Lloyd
firstname.lastname@example.org / email@example.com
Tél: +44 1273 675100
Dr. Gilles Ravot
Tel: (33) 04 66 70 64 64
Publication of a paper on cell-free functional screening for enzyme discovery
Protéus has published an exciting paper concerning the use of a cell-free protein expression technology for screening genomic libraries for new enzymes.
Cell-free expression systems are advantageous in permitting a more comprehensive screen under conditions optimised for the desired enzyme activity than cell-based expression.
Most interestingly, we show in the paper that multiple ORFs can be successfully expressed from a single, multicistronic DNA fragment.
Altogether the approach allows to screen a library of more than 5,000 different enzymes variants within less than one day.
Ref: Lyubov A. Ryabova, Sabrina Guillemer, Stéphanie Pallas, Cécile Persillon, Fabrice Lefèvre, Jean-Michel Masson, and Gilles Ravot
A quick in vitro pathway from prokaryotic genomic libraries to enzyme discovery
Biotechniques 45:63-68 (July 2008)
For more details, please refer to Biotechniques 45:63-68 (July 2008)